{"id":967271,"date":"2026-05-27T07:12:20","date_gmt":"2026-05-27T11:12:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\/"},"modified":"2026-05-27T07:12:20","modified_gmt":"2026-05-27T11:12:20","slug":"vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\/","title":{"rendered":"Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n WASHINGTON<\/span>, May 27, 2026<\/span> \/PRNewswire\/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to imsidolimab, a high\u2011affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP).<\/p>\n

\n

\n
\n \"Vanda
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Imsidolimab inhibits interleukin\u201136 (IL\u201136) receptor signaling, addressing the deficiency in the endogenous IL\u201136 receptor antagonist regulator that is commonly observed in patients with GPP.1<\/sup><\/p>\n

The MHLW grants orphan drug designation to medicines intended to treat rare diseases with significant unmet medical need. In Japan, approximately 2,200 people have been diagnosed with GPP.2<\/sup>\u00a0 IL36RN<\/i> genetic variants\u2014which are associated with dysregulation of the IL\u201136 pathway\u2014are enriched in the Japanese population, including well\u2011characterized founder families in Hokkaido.3<\/sup><\/p>\n

In Japan, orphan drug designation provides development incentives, including subsidies for research and development costs, as well as the potential for up to 10 years of market exclusivity following approval.<\/p>\n

This designation follows similar regulatory recognition in the United States and underscores the global interest in the potential of imsidolimab to address the significant unmet medical needs of patients with GPP, a rare and severe inflammatory skin disease associated with systemic complications and increased mortality.4<\/sup><\/p>\n

\n References<\/b>\n <\/p>\n

    \n
  1. Smieszek, S.\u00a0et al.<\/i>\u00a0Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis.\u00a0NEJM Evidence<\/i>\u00a05<\/b>, (2026).\u00a0<\/li>\n
  2. Ministry of Health Labour and Welfare (MHLW), “Pustular psoriasis (generalized type) (Designated Intractable Disease 37),” Japan Intractable Diseases Information Center. Accessed: Mar. 10, 2026. [Online]. Available: https:\/\/www.nanbyou.or.jp\/entry\/168<\/a><\/li>\n
  3. H. Fujita, R. Iwasaki, S. Tsuboi, Y. Murashiuma, and M. Akiyama, “Regional differences in the prevalence of generalized pustular psoriasis in Japan,” J. Dermatol., vol. 51, no. 3, pp. 380\u2013390, Mar. 2024, doi: 10.1111\/1346-8138.17089.<\/li>\n
  4. H. Miyachi et al., “Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients in a nationwide inpatient database in Japan,” J. Am. Acad. Dermatol., vol. 86, no. 6, pp. 1266\u20131274, Jun. 2022, doi: 10.1016\/j.jaad.2021.06.008.<\/li>\n<\/ol>\n

    \n About Vanda Pharmaceuticals Inc.<\/b>\n <\/p>\n

    Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com<\/a> and follow us on X @vandapharma.<\/p>\n

    \n CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS<\/b>\n <\/p>\n

    Various statements in this press release, including, but not limited to, statements regarding the therapeutic potential of imsidolimab for patients with GPP and the potential to extend regulatory and patent exclusivity for imsidolimab into the late 2030s, are “forward\u2011looking statements” within the meaning of the securities laws. All statements other than statements of historical fact are statements that could be deemed forward\u2011looking statements. Forward\u2011looking statements are based on current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda’s forward-looking statements include, among others, Vanda’s ability to obtain regulatory approval of, and to successfully commercialize, imsidolimab for the treatment of GPP and Vanda’s ability to satisfy the conditions necessary to extend regulatory and patent exclusivity for imsidolimab into the late 2030s. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward\u2011looking statements in this press release should be evaluated together with the risks and uncertainties described in the sections titled “Cautionary Note Regarding Forward\u2011Looking Statements,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Vanda’s most recent Annual Report on Form 10\u2011K, as updated by Vanda’s subsequent Quarterly Reports on Form 10\u2011Q, Current Reports on Form 8\u2011K, and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov<\/a>.<\/p>\n

    All forward\u2011looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth herein. Vanda cautions investors not to place undue reliance on forward\u2011looking statements. The information contained in this press release is provided as of the date hereof, and Vanda undertakes no obligation, and expressly disclaims any obligation, to update or revise any forward\u2011looking statements, whether as a result of new information, future events, or otherwise, except as required by law.<\/p>\n

    \n Corporate Contact:<\/b>\n <\/p>\n

    Kevin Moran
    Senior Vice President, Chief Financial Officer and Treasurer
    Vanda Pharmaceuticals Inc.
    202-734-3400
    pr@vandapharma.com<\/a><\/p>\n

    Jim Golden \/ Jack Kelleher \/ Dan Moore
    Collected Strategies
    VANDA-CS@collectedstrategies.com<\/a><\/p>\n

    Follow us on X @vandapharma<\/p>\n

    \n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis-302782517.html<\/a><\/p>\n

    SOURCE Vanda Pharmaceuticals Inc.<\/p>\n<\/p><\/div>\n

    \"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

    PR Newswire WASHINGTON, May 27, 2026 \/PRNewswire\/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to imsidolimab, a high\u2011affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP). Imsidolimab inhibits interleukin\u201136 (IL\u201136) receptor signaling, addressing the deficiency in the endogenous IL\u201136 receptor antagonist regulator that is commonly observed in patients with GPP.1 The MHLW grants orphan drug designation to medicines intended to treat rare diseases with significant unmet medical need. In Japan, approximately 2,200 people have been diagnosed with GPP.2\u00a0 IL36RN genetic variants\u2014which are associated with dysregulation of the IL\u201136 pathway\u2014are enriched in the Japanese population, including well\u2011characterized founder families … <\/p>\n

    Continue reading “Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-967271","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nVanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire WASHINGTON, May 27, 2026 \/PRNewswire\/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to imsidolimab, a high\u2011affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP). Imsidolimab inhibits interleukin\u201136 (IL\u201136) receptor signaling, addressing the deficiency in the endogenous IL\u201136 receptor antagonist regulator that is commonly observed in patients with GPP.1 The MHLW grants orphan drug designation to medicines intended to treat rare diseases with significant unmet medical need. In Japan, approximately 2,200 people have been diagnosed with GPP.2\u00a0 IL36RN genetic variants\u2014which are associated with dysregulation of the IL\u201136 pathway\u2014are enriched in the Japanese population, including well\u2011characterized founder families … Continue reading "Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-27T11:12:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2090054\/VandaLogo_v1.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis\",\"datePublished\":\"2026-05-27T11:12:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\\\/\"},\"wordCount\":768,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2090054\\\/VandaLogo_v1.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\\\/\",\"name\":\"Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2090054\\\/VandaLogo_v1.jpg\",\"datePublished\":\"2026-05-27T11:12:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2090054\\\/VandaLogo_v1.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2090054\\\/VandaLogo_v1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\/","og_locale":"en_US","og_type":"article","og_title":"Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis - Market Newsdesk","og_description":"PR Newswire WASHINGTON, May 27, 2026 \/PRNewswire\/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to imsidolimab, a high\u2011affinity humanized immunoglobulin G4 (IgG4) monoclonal antibody, for the treatment of generalized pustular psoriasis (GPP). Imsidolimab inhibits interleukin\u201136 (IL\u201136) receptor signaling, addressing the deficiency in the endogenous IL\u201136 receptor antagonist regulator that is commonly observed in patients with GPP.1 The MHLW grants orphan drug designation to medicines intended to treat rare diseases with significant unmet medical need. In Japan, approximately 2,200 people have been diagnosed with GPP.2\u00a0 IL36RN genetic variants\u2014which are associated with dysregulation of the IL\u201136 pathway\u2014are enriched in the Japanese population, including well\u2011characterized founder families … Continue reading \"Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-27T11:12:20+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2090054\/VandaLogo_v1.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis","datePublished":"2026-05-27T11:12:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\/"},"wordCount":768,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2090054\/VandaLogo_v1.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\/","name":"Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2090054\/VandaLogo_v1.jpg","datePublished":"2026-05-27T11:12:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2090054\/VandaLogo_v1.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2090054\/VandaLogo_v1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/967271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=967271"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/967271\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=967271"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=967271"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=967271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}